Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma 4Lymphoma, T-Cell 3Prostatic Neoplasms 2Neoplasm Metastasis 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 44Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 13irinotecan sucrosofate 11Injections 10Cisplatin 10fludarabine 8Pemetrexed 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × romidepsin × Clear all
NCT00379639 2019-10-30

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

Celgene

Phase 1 Completed
36 enrolled 17 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡